TAS-102 in refractory colorectal cancer: caution is needed
Mené sur 112 patients atteints d'un cancer colorectal métastatique réfractaire, cet essai japonais de phase II évalue l'efficacité et la toxicité d'un composé appelé TAS-102, un nouvel agent nucléosidique antitumoral par voie orale
The purpose of a randomised comparative phase 2 trial is to decide whether to continue to phase 3. Other variables affect this decision, but the most important factor is whether enough activity is recorded. In The Lancet Oncology , Takayuki Yoshino and colleagues present evidence for the activity of TAS-102 (an oral nucleoside antitumour agent) compared with placebo in the setting of refractory metastatic colorectal cancer (hazard ratio [HR ] for death 0·56; 80% CI 0·44—0·71, 95% CI 0·39—0·81; p=0·0 ...
The Lancet Oncology , commentaire, 2011